English
 
User Manual Privacy Policy Disclaimer Contact us
  Advanced SearchBrowse

Item

ITEM ACTIONSEXPORT
  Epitopes of naturally acquired and vaccine-induced anti-Ebola virus glycoprotein antibodies in single amino acid resolution

Heidepriem, J., Krähling, V., Dahlke, C., Wolf, T., Klein, F., Addo, M. M., et al. (2020). Epitopes of naturally acquired and vaccine-induced anti-Ebola virus glycoprotein antibodies in single amino acid resolution. Biotechnology Journal, 2000069. doi:10.1002/biot.202000069.

Item is

Basic

show hide
Item Permalink: http://hdl.handle.net/21.11116/0000-0006-823F-1 Version Permalink: http://hdl.handle.net/21.11116/0000-0006-9589-7
Genre: Journal Article

Files

show Files
hide Files
:
Manuscript.pdf (Any fulltext), 2MB
 
File Permalink:
-
Name:
Manuscript.pdf
Description:
-
Visibility:
Restricted (Max Planck Institute of Colloids and Interfaces, MTKG; )
MIME-Type / Checksum:
application/pdf
Technical Metadata:
Copyright Date:
-
Copyright Info:
-
License:
-

Locators

show

Creators

show
hide
 Creators:
Heidepriem, Jasmin1, Author              
Krähling, Verena, Author
Dahlke, Christine, Author
Wolf, Timo, Author
Klein, Florian, Author
Addo, Marylyn M., Author
Becker, Stephan, Author
Löffler, Felix F.1, Author              
Affiliations:
1Felix Löffler, Biomolekulare Systeme, Max Planck Institute of Colloids and Interfaces, Max Planck Society, ou_2385692              

Content

show
hide
Free keywords: EBOV, epitope mapping, human sera, neutralizing antibodies, rVSV-ZEBOV
 Abstract: Abstract The Ebola virus (EBOV) can cause severe infections in humans, leading to a fatal outcome in a high percentage of cases. Neutralizing antibodies against the EBOV surface glycoprotein (GP) can prevent infections, demonstrating a straightforward way for an efficient vaccination strategy. Meanwhile, many different anti-EBOV antibodies have been identified, whereas the exact binding epitopes are often unknown. Here, we present the analysis of serum samples from an EBOV vaccine trial with the viral vector vaccine rVSV-ZEBOV and an Ebola virus disease (EVD) survivor, using high-density peptide arrays. In this proof-of-principle study, we detected distinct IgG and IgM antibodies binding to different epitopes of EBOV GP: By mapping the whole GP as overlapping peptide fragments, we found new epitopes and confirmed epitopes from the literature. Furthermore, we could validate the highly selective binding epitope of a neutralizing monoclonal anti-EBOV GP antibody. This shows that peptide arrays can be a valuable tool to study the humoral immune response to vaccines in patients and to support Ebola vaccine development. This article is protected by copyright. All rights reserved

Details

show
hide
Language(s): eng - English
 Dates: 2020-05-28
 Publication Status: Published online
 Pages: -
 Publishing info: -
 Table of Contents: -
 Rev. Method: -
 Identifiers: DOI: 10.1002/biot.202000069
 Degree: -

Event

show

Legal Case

show

Project information

show

Source 1

show
hide
Title: Biotechnology Journal
  Alternative Title : Biotechnol. J.
Source Genre: Journal
 Creator(s):
Affiliations:
Publ. Info: Weinheim : Wiley-VCH
Pages: - Volume / Issue: - Sequence Number: 2000069 Start / End Page: - Identifier: ISBN: 1860-6768